Literature DB >> 20362228

Cytogenetic studies in acute leukemia patients relapsing after allogeneic stem cell transplantation.

Martin Schmidt-Hieber1, Igor W Blau, Gregor Richter, Seval Türkmen, Christiane Bommer, Gundula Thiel, Heidemarie Neitzel, Andrea Stroux, Lutz Uharek, Eckhard Thiel, Olga Blau.   

Abstract

We analyzed karyotype stability in 22 patients with acute leukemia at relapse or disease progression after allogeneic stem cell transplantation (allo-SCT). Karyotypes before and at relapse after allo-SCT were different in 15 patients (68%), the most frequent type being clonal evolution either alone or combined with clonal devolution (13 patients). Patients with and without a karyotype change did not differ significantly in overall survival (OS) (median, 399 vs. 452 days; P = 0.889) and survival after relapse (median, 120 vs. 370 days; P = 0.923). However, acquisition of additional structural chromosome 1 abnormalities at relapse after allo-SCT occurred more frequently than expected and was associated with reduced OS (median, 125 vs. 478 days; P = 0.008) and shorter survival after relapse (median, 37 vs. 370 days; P = 0.002). We identified a previously undescribed clonal evolution involving t(15;17) without PML-RARA rearrangement in an AML patient. We conclude that a karyotype change is common at relapse after allo-SCT in acute leukemia patients. Moreover, our data suggest that additional structural chromosome 1 abnormalities are overrepresented at relapse after allo-SCT in these patients and, in contrast to a karyotype change per se, are associated with reduced OS and shorter survival after relapse. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20362228     DOI: 10.1016/j.cancergencyto.2010.01.005

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  5 in total

Review 1.  Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance.

Authors:  Marcel van den Brink; Markus Uhrberg; Lorenz Jahn; John F DiPersio; Michael A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

Review 2.  Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.

Authors:  T Bochtler; S Fröhling; A Krämer
Journal:  Leukemia       Date:  2015-02-12       Impact factor: 11.528

3.  Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Authors:  Lynn Quek; Paul Ferguson; Marlen Metzner; Ikhlaaq Ahmed; Alison Kennedy; Catherine Garnett; Sally Jeffries; Claudia Walter; Kim Piechocki; Adele Timbs; Robert Danby; Manoj Raghavan; Andrew Peniket; Mike Griffiths; Andrew Bacon; Janice Ward; Keith Wheatley; Paresh Vyas; Charles Craddock
Journal:  Blood Adv       Date:  2016-12-14

Review 4.  Biology of Disease Relapse in Myeloid Disease: Implication for Strategies to Prevent and Treat Disease Relapse After Stem-Cell Transplantation.

Authors:  Joseph C Rimando; Matthew J Christopher; Michael P Rettig; John F DiPersio
Journal:  J Clin Oncol       Date:  2021-01-12       Impact factor: 44.544

5.  Karyotypic change between diagnosis and relapse as a predictor of salvage therapy outcome in AML patients.

Authors:  Yundeok Kim; Jieun Jang; Shin Yong Hyun; Dohyu Hwang; Soo Jeong Kim; Jin Seok Kim; Jun-Won Cheong; Yoo Hong Min
Journal:  Blood Res       Date:  2013-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.